Therapeutic modulation of Notch signalling-are we there yet?

Nature Reviews Drug Discovery

Volumn 13, Issue 5, 2014, Pages 357-378

  Andersson, Emma R ^a   Lendahl, Urban ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 906024; DEMCIZUMAB; GAMMA SECRETASE INHIBITOR; MED I0639; MEDI 0639; MK 0752; MP 21M18; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; OMP 59R5; PANOBINOSTAT; PF 3084014; RESVERATROL; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALAGILLE SYNDROME; ALZHEIMER DISEASE; BREAST CANCER; CADASIL; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL TUMOR; GLIOMA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC SYSTEM; HUMAN; LIGAND BINDING; LIVER FIBROSIS; METASTATIC COLORECTAL CANCER; MOLECULAR PATHOLOGY; NOISE INJURY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; T CELL LEUKEMIA; TISSUE DISTRIBUTION;

ANIMALS; CADASIL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA; RECEPTORS, NOTCH; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84899626029     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4252     Document Type: Review

References (299)

1. Ellisen, L. W. et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661 (1991). (Pubitemid 121001701)
2. Joutel, A. et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383, 707-710 (1996). (Pubitemid 26360644)
3. Oda, T. et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nature Genet. 16, 235-242 (1997).
4. McDaniell, R. et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am. J. Hum. Genet. 79, 169-173 (2006). (Pubitemid 43927389)
5. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
6. Fabbri, G. et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208, 1389-1401 (2011).
7. Sparrow, D. B., Guill-Navarro, E., Fatkin, D. & Dunwoodie, S. L. Mutation of Hairy-and-Enhancer-of-Split-7 in humans causes spondylocostal dysostosis. Hum. Mol. Genet. 17, 3761-3766 (2008).
8. Sparrow, D. B. et al. Mutation of the LUNATIC FRINGE gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. Am. J. Hum. Genet. 78, 28-37 (2006). (Pubitemid 41833157)
9. Whittock, N. V. et al. Mutated MESP2 causes spondylocostal dysostosis in humans. Am. J. Hum. Genet. 74, 1249-1254 (2004). (Pubitemid 38669323)
10. Andersson, E. R., Sandberg, R. & Lendahl, U. Notch signaling: simplicity in design, versatility in function. Development 138, 3593-3612 (2011).
11. Guruharsha, K. G., Kankel, M. W. & Artavanis-Tsakonas, S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nature Rev. Genet. 13, 654-666 (2012).
12. Shao, H., Huang, Q. & Liu, Z.-J. Targeting Notch signaling for cancer therapeutic intervention. Adv. Pharmacol. 65, 191-234 (2012).
13. Groth, C. & Fortini, M. E. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin. Cell Dev. Biol. 23, 465-472 (2012).
14. Bray, S. J. Notch signalling: a simple pathway becomes complex. Nature Rev. Mol. Cell. Biol. 7, 678-689 (2006). (Pubitemid 44268213)
15. Coleman, M. L. et al. Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J. Biol. Chem. 282, 24027-24038 (2007). (Pubitemid 47328043)
16. Zheng, X. et al. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc. Natl Acad. Sci. USA 105, 3368-3373 (2008). (Pubitemid 351723559)
17. Espinosa, L., Ingles-Esteve, J., Aguilera, C. & Bigas, A. Phosphorylation by glycogen synthase kinase-3β down-regulates Notch activity, a link for Notch and Wnt pathways. J. Biol. Chem. 278, 32227-32235 (2003). (Pubitemid 37048415)
18. King, B. et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 153, 1552-1566 (2013).
19. Richards, G. S. & Degnan, B. M. The dawn of developmental signaling in the metazoa. Cold Spring Harb. Symp. Quant. Biol. 74, 81-90 (2009).
20. Ladi, E. et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J. Cell Biol. 170, 983-992 (2005). (Pubitemid 41306297)
21. Geffers, I. et al. Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo. J. Cell Biol. 178, 465-476 (2007). (Pubitemid 47196154)
22. Yamamoto, S. et al. A mutation in EGF repeat-8 of Notch discriminates between Serrate/Jagged and Delta family ligands. Science 338, 1229-1232 (2012).
23. Andrawes, M. B. et al. Intrinsic selectivity of Notch 1 for Delta-like 4 over Delta-like 1. J. Biol. Chem. 288, 25477-25489 (2013).
24. Van de Walle, I. et al. Specific Notch receptor-ligand interactions control human TCR-aαβ/ γθ development by inducing differential Notch signal strength. J. Exp. Med. 210, 683-697 (2013).
25. Panin, V. M., Papayannopoulos, V., Wilson, R. & Irvine, K. D. Fringe modulates Notch-ligand interactions. Nature 387, 908-912 (1997). (Pubitemid 27289592)
26. Hicks, C. et al. Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2. Nature Cell Biol. 2, 515-520 (2000).
27. Rana, N. A. & Haltiwanger, R. S. Fringe benefits: functional and structural impacts of O-glycosylation on the extracellular domain of Notch receptors. Curr. Opin. Struct. Biol. 21, 583-589 (2011).
28. Jin, S. et al. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKaα/IKKβ. Oncogene 32, 4892-4902 (2012).
29. Shimizu, K. et al. Mouse Jagged1 physically interacts with Notch2 and other Notch receptors. Assessment by quantitative methods. J. Biol. Chem. 274, 32961-32969 (1999). (Pubitemid 129535335)
30. Rebay, I. et al. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell 67, 687-699 (1991). (Pubitemid 121001482)
31. Falk, R. et al. Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells. Methods 58, 69-78 (2012).
32. Liu, S. K. et al. Delta-like ligand 4-Notch blockade and tumor radiation response. J. Natl Cancer Inst. 103, 1-21 (2011).
33. Ohishi, K., Varnum-Finney, B., Serda, R. E., Anasetti, C. & Bernstein, I. D. The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells. Blood 98, 1402-1407 (2001).
34. +CD38- cord blood cells. J. Clin. Invest. 110, 1165-1174 (2002). (Pubitemid 35215897)
35. Ohishi, K. et al. Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1. Blood 95, 2847-2854 (2000). (Pubitemid 30235894)
36. Hicks, C. et al. A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signaling. J. Neurosci. Res. 68, 655-667 (2002). (Pubitemid 34594983)
37. Czajkowsky, D. M., Hu, J., Shao, Z. & Pleass, R. J. Fc-fusion proteins: new developments and future perspectives. EMBO Mol. Med. 4, 1015-1028 (2012).
38. Gonçalves, R. M., Martins, M. C. L., Almeida-Porada, G. & Barbosa, M. A. Induction of notch signaling by immobilization of jagged-1 on self-assembled monolayers. Biomaterials 30, 6879-6887 (2009).
39. Toda, H., Yamamoto, M., Kohara, H. & Tabata, Y. Orientation-regulated immobilization of Jagged1 on glass substrates for ex vivo proliferation of a bone marrow cell population containing hematopoietic stem cells. Biomaterials 32, 6920-6928 (2011).
40. Varnum-Finney, B., Brashem-Stein, C. & Bernstein, I. D. Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. Blood 101, 1784-1789 (2003). (Pubitemid 36237574)
41. Conboy, I. M., Conboy, M. J., Smythe, G. M. & Rando, T. A. Notch-mediated restoration of regenerative potential to aged muscle. Science 302, 1575-1577 (2003). (Pubitemid 37475703)
42. Small, D. et al. Soluble Jagged 1 represses the function of its transmembrane form to induce the formation of the Src-dependent chord-like phenotype. J. Biol. Chem. 276, 32022-32030 (2001).
43. Trifonova, R. et al. The non-transmembrane form of Delta1, but not of Jagged1, induces normal migratory behavior accompanied by fibroblast growth factor receptor 1-dependent transformation. J. Biol. Chem. 279, 13285-13288 (2004). (Pubitemid 38468847)
44. Li, L. et al. The human homolog of rat Jagged1 expressed by marrow stroma inhibits differentiation of 32D cells through interaction with Notch1. Immunity 8, 43-55 (1998). (Pubitemid 28097822)
45. Kannan, S. et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J. Exp. Med. 210, 321-337 (2013).
46. Androutsellis-Theotokis, A. et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 442, 823-826 (2006). (Pubitemid 44258913)
47. Lu, J. et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23, 171-185 (2013).
48. Nehring, L. C., Miyamoto, A., Hein, P. W., Weinmaster, G. & Shipley, J. M. The extracellular matrix protein MAGP-2 interacts with Jagged1 and induces its shedding from the cell surface. J. Biol. Chem. 280, 20349-20355 (2005). (Pubitemid 40776733)
49. Chillakuri, C. R. et al. Structural analysis uncovers lipid-binding properties of Notch ligands. Cell Rep. 5, 861-867 (2013).
50. Cordle, J. et al. A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nature Struct. Mol. Biol. 15, 849-857 (2008).
51. Logeat, F. et al. The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc. Natl Acad. Sci. USA 95, 8108-8112 (1998). (Pubitemid 28326074)
52. Gordon, W. R. et al. Effects of S1 cleavage on the structure, surface export, and signaling activity of human Notch1 and Notch2. PLoS ONE 4, e6613 (2009).
53. Bush, G. et al. Ligand-induced signaling in the absence of furin processing of Notch1. Dev. Biol. 229, 494-502 (2001). (Pubitemid 32108708)
54. Kidd, S. & Lieber, T. Furin cleavage is not a requirement for Drosophila Notch function. Mech. Dev. 115, 41-51 (2002). (Pubitemid 34615666)
55. Seidah, N. G. & Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nature Rev. Drug Discov. 11, 367-383 (2012).
56. Fernandez-Valdivia, R. et al. Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi. Development 138, 1925-1934 (2011).
57. Acar, M. et al. Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is required for Notch signaling. Cell 132, 247-258 (2008). (Pubitemid 351172433)
58. Shi, S. & Stanley, P. Protein O-fucosyltransferase 1 is an essential component of Notch signaling pathways. Proc. Natl Acad. Sci. USA 100, 5234-5239 (2003). (Pubitemid 36542688)
59. Sethi, M. K. et al. Identification of glycosyltransferase 8 family members as xylosyltransferases acting on O-glucosylated Notch epidermal growth factor repeats. J. Biol. Chem. 285, 1582-1586 (2010).
60. Goode, S. & Perrimon, N. Brainiac and Fringe are similar pioneer proteins that impart specificity to notch signaling during Drosophila development. Cold Spring Harb. Symp. Quant. Biol. 62, 177-184 (1997). (Pubitemid 28198535)
61. Moloney, D. J. et al. Fringe is a glycosyltransferase that modifies Notch. Nature 406, 369-375 (2000). (Pubitemid 30625549)
62. Brückner, K., Perez, L., Clausen, H. & Cohen, S. Glycosyltransferase activity of Fringe modulates Notch-Delta interactions. Nature 406, 411-415 (2000). (Pubitemid 30625560)
63. Wang, X. & Ha, T. Defining single molecular forces required to activate integrin and notch signaling. Science 340, 991-994 (2013).
64. Hansson, E. M. et al. Control of Notch-ligand endocytosis by ligand-receptor interaction. J. Cell Sci. 123, 2931-2942 (2010).
65. Nichols, J. T. et al. DSL ligand endocytosis physically dissociates Notch1 heterodimers before activating proteolysis can occur. J. Cell Biol. 176, 445-458 (2007).
66. Meloty-Kapella, L. et al. Optical tweezers studies on Notch: single-molecule interaction strength is independent of ligand endocytosis. Dev. Cell 22, 1313-1320 (2012).
67. Brou, C. et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 5, 207-216 (2000). (Pubitemid 30628080)
68. Stephenson, N. L. & Avis, J. M. Direct observation of proteolytic cleavage at the S2 site upon forced unfolding of the Notch negative regulatory region. Proc. Natl Acad. Sci. USA 109, E2757-E2765 (2012).
69. Parks, A. L., Klueg, K. M., Stout, J. R. & Muskavitch, M. A. Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. Development 127, 1373-1385 (2000). (Pubitemid 30232589)
70. Mumm, J. S. et al. A ligand-induced extracellular cleavage regulates gamma;-secretase-like proteolytic activation of Notch1. Mol. Cell 5, 197-206 (2000). (Pubitemid 30628079)
71. Van Tetering, G. & Vooijs, M. Proteolytic cleavage of Notch: "HIT and RUN". Curr. Mol. Med. 11, 255-269 (2011).
72. Cousin, H., Abbruzzese, G., Kerdavid, E., Gaultier, A. & Alfandari, D. Translocation of the cytoplasmic domain of ADAM13 to the nucleus is essential for calpain8-a expression and cranial neural crest cell migration. Dev. Cell 20, 256-263 (2011).
73. Tousseyn, T. et al. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma;-secretase. J. Biol. Chem. 284, 11738-11747 (2009).
74. Wu, Y. et al. Therapeutic antibody targeting of individual Notch receptors. Nature 464, 1052-1057 (2010).
75. De Strooper, B. et al. A presenilin-1-dependent gamma;-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522 (1999).
76. Struhl, G. & Greenwald, I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398, 522-525 (1999).
77. Schroeter, E. H., Kisslinger, J. A. & Kopan, R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393, 382-386 (1998). (Pubitemid 28269713)
78. Gupta-Rossi, N. et al. Monoubiquitination and endocytosis direct gamma;-secretase cleavage of activated Notch receptor. J. Cell Biol. 166, 73-83 (2004). (Pubitemid 38931918)
79. Sorensen, E. B. & Conner, S. gamma;-secretase-dependent cleavage initiates Notch signaling from the plasma membrane. Traffic 11, 1234-1245 (2010).
80. Tagami, S. et al. Regulation of Notch signaling by dynamic changes in the precision of S3 cleavage of Notch-1. Mol. Cell. Biol. 28, 165-176 (2008).
81. Vaccari, T., Lu, H., Kanwar, R., Fortini, M. E. & Bilder, D. Endosomal entry regulates Notch receptor activation in Drosophila melanogaster. J. Cell Biol. 180, 755-762 (2008). (Pubitemid 351397775)
82. Okochi, M. et al. Presenilins mediate a dual intramembranous gamma;-secretase cleavage of Notch-1. EMBO J. 21, 5408-5416 (2002). (Pubitemid 35231020)
83. Okochi, M. et al. Secretion of the Notch-1 Aβ-like peptide during Notch signaling. J. Biol. Chem. 281, 7890-7898 (2006). (Pubitemid 43847405)
84. Krejcv, A. & Bray, S. Notch activation stimulates transient and selective binding of Su(H)/CSL to target enhancers. Genes Dev. 21, 1322-1327 (2007). (Pubitemid 46871036)
85. Castel, D. et al. Dynamic binding of RBPJ is determined by Notch signaling status. Genes Dev. 27, 1059-1071 (2013).
86. Wilson, J. J. & Kovall, R. A. Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell 124, 985-996 (2006). (Pubitemid 43344238)
87. Nam, Y., Sliz, P., Song, L., Aster, J. C. & Blacklow, S. C. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 124, 973-983 (2006). (Pubitemid 43344237)
88. Weng, A. P. et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of Notch signaling. Mol. Cell. Biol. 23, 655-664 (2003). (Pubitemid 36050558)
89. Maillard, I. et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 104, 1696-1702 (2004). (Pubitemid 39202276)
90. Maillard, I. et al. The requirement for Notch signaling at the β-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor. J. Exp. Med. 203, 2239-2245 (2006). (Pubitemid 44498358)
91. Maillard, I. et al. Canonical Notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell 2, 356-366 (2008). (Pubitemid 351455243)
92. Osanyingbemi-Obidi, J., Dobromilskaya, I., Illei, P. B., Hann, C. L. & Rudin, C. M. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol. Cancer Res. 9, 1746-1754 (2011).
93. Shen, H. et al. The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev. 20, 675-688 (2006).
94. Saint Just Ribeiro, M. & Wallberg, A. E. Transcriptional mechanisms by the coregulator MAML1. Curr. Protein Pept. Sci. 10, 570-576 (2009).
95. McElhinny, A. S., Li, J.-L. & Wu, L. Mastermind-like transcriptional co-activators: emerging roles in regulating cross talk among multiple signaling pathways. Oncogene 27, 5138-5147 (2008).
96. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 (2009).
97. Yuan, Z., Friedmann, D. R., VanderWielen, B. D., Collins, K. J. & Kovall, R. A. Characterization of CSL (CBF-1, Su(H), Lag-1) mutants reveals differences in signaling mediated by Notch1 and Notch2. J. Biol. Chem. 287, 34904-34916 (2012).
98. Lubman, O. Y., Ilagan, M. X. G., Kopan, R. & Barrick, D. Quantitative dissection of the Notch:CSL interaction: insights into the Notch-mediated transcriptional switch. J. Mol. Biol. 365, 577-589 (2007). (Pubitemid 44960348)
99. Johnson, J. E. & Macdonald, R. J. Notch-independent functions of CSL. Curr. Top. Dev. Biol. 97, 55-74 (2011).
100. Foltz, D. R., Santiago, M. C., Berechid, B. E. & Nye, J. S. Glycogen synthase kinase-3β modulates Notch signaling and stability. Curr. Biol. 12, 1006-1011 (2002). (Pubitemid 34703331)
101. Fryer, C. J., White, J. B. & Jones, K. A. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol. Cell 16, 509-520 (2004). (Pubitemid 39531875)
102. Sjeqvist, M. et al. PKCZ regulates Notch receptor routing and activity in a Notch signaling-dependent manner. Cell Res. http://dx.doi.org/10.1038/cr. 2014.34 (2014).
103. Guarani, V. et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 473, 234-238 (2011).
104. Le Bras, S., Loyer, N. & Le Borgne, R. The multiple facets of ubiquitination in the regulation of Notch signaling pathway. Traffic 12, 149-161 (2011).
105. Hubbard, E. J. A., Wu, G., Kitajewski, J. & Greenwald, I. sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes Dev. 11, 3182-3193 (1997). (Pubitemid 27528058)
106. Tsunematsu, R. et al. Mouse Fbw7/Sel-10/Cdc4 is required for Notch degradation during vascular development. J. Biol. Chem. 279, 9417-9423 (2004). (Pubitemid 38296008)
107. Malyukova, A. et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 67, 5611-5616 (2007). (Pubitemid 46984990)
108. O'Neil, J. et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma;-secretase inhibitors. J. Exp. Med. 204, 1813-1824 (2007). (Pubitemid 47236319)
109. McGill, M. A. & McGlade, C. J. Mammalian Numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J. Biol. Chem. 278, 23196-23203 (2003). (Pubitemid 36830386)
110. Qiu, L. et al. Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J. Biol. Chem. 275, 35734-35737 (2000).
111. Pettersson, S. et al. Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the Notch signalling pathway. Biochem. J. 450, 523-536 (2013).
112. Zhang, J., Liu, M., Su, Y., Du, J. & Zhu, A. J. A targeted in vivo RNAi screen reveals deubiquitinases as new regulators of Notch signaling. G3 2, 1563-1575 (2012).
113. Mupoz-Descalzo, S., Tkocz, K., Balayo, T. & Arias, A. M. Modulation of the ligand-independent traffic of Notch by Axin and Apc contributes to the activation of Armadillo in Drosophila. Development 138, 1501-1506 (2011).
114. Hayward, P., Balayo, T. & Martinez Arias, A. Notch synergizes with axin to regulate the activity of armadillo in Drosophila. Dev. Dyn. 235, 2656-2666 (2006). (Pubitemid 44484501)
115. Hayward, P. et al. Notch modulates Wnt signalling by associating with Armadillo/β-catenin and regulating its transcriptional activity. Development 132, 1819-1830 (2005). (Pubitemid 40691772)
116. Shimizu, T. et al. Stabilized β-catenin functions through TCF/LEF proteins and the Notch/RBP-JK complex to promote proliferation and suppress differentiation of neural precursor cells. Mol. Cell. Biol. 28, 7427-7441 (2008).
117. Yamamizu, K. et al. Convergence of Notch and β-catenin signaling induces arterial fate in vascular progenitors. J. Cell Biol. 189, 325-338 (2010).
118. Axelrod, J. D., Matsuno, K., Artavanis-Tsakonas, S. & Perrimon, N. Interaction between Wingless and Notch signaling pathways mediated by dishevelled. Science 271, 1826-1832 (1996).
119. Mupoz-Descalzo, S. et al. Wingless modulates the ligand independent traffic of Notch through Dishevelled. Fly 4, 182-193 (2010).
120. Blokzijl, A. et al. Cross-talk between the Notch and TGF-β signaling pathways mediated by interaction of the Notch intracellular domain with Smad3. J. Cell Biol. 163, 723-728 (2003). (Pubitemid 37517880)
121. Dahlqvist, C. et al. Functional Notch signaling is required for BMP4-induced inhibition of myogenic differentiation. Development 130, 6089-6099 (2003). (Pubitemid 38008810)
122. Itoh, F. Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J. 23, 541-551 (2004). (Pubitemid 38282386)
123. Gustafsson, M. V. et al. Hypoxia requires Notch signaling to maintain the undifferentiated cell state. Dev. Cell 9, 617-628 (2005). (Pubitemid 41555144)
124. Roti, G. et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell 23, 390-405 (2013).
125. Ilagan, M. X. G. & Kopan, R. Selective blockade of transport via SERCA inhibition: the answer for oncogenic forms of Notch? Cancer Cell 23, 267-269 (2013).
126. Andersen, P., Uosaki, H., Shenje, L. T. & Kwon, C. Non-canonical Notch signaling: emerging role and mechanism. Trends Cell Biol. 22, 257-265 (2012).
127. D'Souza, B., Meloty-Kapella, L. & Weinmaster, G. Canonical and non-canonical Notch ligands. Curr. Top. Dev. Biol. 92, 73-129 (2010).
128. Sandy, A. R., Jones, M. & Maillard, I. Notch signaling and development of the hematopoietic system. Adv. Exp. Med. Biol. 727, 71-88 (2012).
129. Xu, K., Moghal, N. & Egan, S. E. Notch signaling in lung development and disease. Adv. Exp. Med. Biol. 727, 89-98 (2012).
130. Barak, H., Surendran, K. & Boyle, S. C. The role of Notch signaling in kidney development and disease. Adv. Exp. Med. Biol. 727, 99-113 (2012).
131. Kume, T. Ligand-dependent Notch signaling in vascular formation. Adv. Exp. Med. Biol. 727, 210-222 (2012).
132. Murata, J., Ikeda, K. & Okano, H. Notch signaling and the developing inner ear. Adv. Exp. Med. Biol. 727, 161-173 (2012).
133. Aubin-Houzelstein, G. Notch signaling and the developing hair follicle. Adv. Exp. Med. Biol. 727, 142-160 (2012).
134. Mead, T. J. & Yutzey, K. E. Notch signaling and the developing skeleton. Adv. Exp. Med. Biol. 727, 114-130 (2012).
135. Clements, W. K. et al. A somitic Wnt16/Notch pathway specifies haematopoietic stem cells. Nature 474, 220-224 (2011).
136. Han, H. et al. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int. Immunol. 14, 637-645 (2002). (Pubitemid 34649719)
137. Tanigaki, K. et al. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nature Immunol. 3, 443-450 (2002). (Pubitemid 34520793)
138. Ciofani, M. & Zípiga-Pflócker, J. C. Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism. Nature Immunol. 6, 881-888 (2005). (Pubitemid 43090442)
139. Lobry, C. et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J. Exp. Med. 210, 301-319 (2013).
140. Schroeder, T. & Just, U. Notch signalling via RBP-J promotes myeloid differentiation. EMBO J. 19, 2558-2568 (2000). (Pubitemid 30323545)
141. Bigas, A., Martin, D. I. & Milner, L. A. Notch1 and Notch2 inhibit myeloid differentiation in response to different cytokines. Mol. Cell. Biol. 18, 2324-2333 (1998). (Pubitemid 28152679)
142. Oh, P. et al. In vivo mapping of notch pathway activity in normal and stress hematopoiesis. Cell Stem Cell 13, 190-204 (2013).
143. Klinakis, A. et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473, 230-233 (2011).
144. + hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J. Immunol. 180, 1598-1608 (2008).
145. Bigas, A., D'Altri, T. & Espinosa, L. The Notch pathway in hematopoietic stem cells. Curr. Top. Microbiol. Immunol. 360, 1-18 (2012).
146. Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269-271 (2004). (Pubitemid 39336870)
147. Thompson, B. J. et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825-1835 (2007). (Pubitemid 47236320)
148. Henkel, T., Ling, P. D., Hayward, S. D. & Peterson, M. G. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein JK. Science 265, 92-95 (1994).
149. Cotter, M., Callahan, J., Aster, J. & Robertson, E. Intracellular forms of human NOTCH1 functionally activate essential Epstein-Barr virus major latent promoters in the Burkitt's lymphoma BJAB cell line but repress these promoters in Jurkat cells. J. Virol. 74, 1486-1494 (2000). (Pubitemid 30044099)
150. Strobl, L. J. et al. Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J. Virol. 74, 1727-1735 (2000). (Pubitemid 30434029)
151. Callahan, J., Aster, J., Sklar, J., Kieff, E. & Robertson, E. S. Intracellular forms of human NOTCH1 interact at distinctly different levels with RBP-jkappa in human B and T cells. Leukemia 14, 84-92 (2000). (Pubitemid 30068377)
152. Kridel, R. et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119, 1963-1971 (2012).
153. Dumortier, A. et al. Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin. PLoS ONE 5, e9258 (2010).
154. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013).
155. Grieselhuber, N. R. et al. Notch signaling in acute promyelocytic leukemia. Leukemia 27, 1548-1557 (2013).
156. Wang, Q., Zhao, N., Kennard, S. & Lilly, B. Notch2 and Notch3 function together to regulate vascular smooth muscle development. PLoS ONE 7, e37365 (2012).
157. Domenga, V. et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev. 18, 2730-2735 (2004). (Pubitemid 39507766)
158. Liu, H., Zhang, W., Kennard, S., Caldwell, R. B. & Lilly, B. Notch3 is critical for proper angiogenesis and mural cell investment. Circ. Res. 107, 860-870 (2010).
159. Oka, C. et al. Disruption of the mouse RBP-JK gene results in early embryonic death. Development 121, 3291-3301 (1995).
160. Gale, N. W. et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl Acad. Sci. USA 101, 15949-15954 (2004). (Pubitemid 39507907)
161. Xue, Y. et al. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum. Mol. Genet. 8, 723-730 (1999). (Pubitemid 29189039)
162. McCright, B. et al. Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. Development 128, 491-502 (2001). (Pubitemid 32229592)
163. Krebs, L. T. et al. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 14, 1343-1352 (2000). (Pubitemid 30397078)
164. Lawson, N. D., Vogel, A. M. & Weinstein, B. M. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev. Cell 3, 127-136 (2002). (Pubitemid 34778401)
165. Zhong, T. P., Childs, S., Leu, J. P. & Fishman, M. C. Gridlock signalling pathway fashions the first embryonic artery. Nature 414, 216-220 (2001). (Pubitemid 33051237)
166. Jakobsson, L. et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nature Cell Biol. 12, 943-953 (2010).
167. Liu, Z. et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J. Clin. Invest. 121, 800-808 (2011).
168. Yan, M. et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 463, E6-E7 (2010).
169. Mosquera, J.-M. et al. Novel MIR143-NOTCH fusions in benign and malignant glomus tumors. Genes. Chromosomes Cancer 52, 1075-1087 (2013).
170. Joutel, A. et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350, 1511-1515 (1997). (Pubitemid 28036555)
171. Monet-Leprêtre, M. et al. Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. Brain 136, 1830-1845 (2013).
172. Joutel, A. et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J. Clin. Invest. 120, 433-445 (2010).
173. Li, X. et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nature Med. 15, 1289-1297 (2009).
174. Yu, Y.-R. A., Mao, L., Piantadosi, C. A. & Gunn, M. D. CCR2
175. De la Pompa, J. L. & Epstein, J. A. Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev. Cell 22, 244-254 (2012).
176. Timmerman, L. A. et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 18, 99-115 (2004). (Pubitemid 38090691)
177. Grego-Bessa, J. et al. Notch signaling is essential for ventricular chamber development. Dev. Cell 12, 415-429 (2007).
178. High, F. A. et al. Murine Jagged1/Notch signaling in the second heart field orchestrates Fgf8 expression and tissue-tissue interactions during outflow tract development. J. Clin. Invest. 119, 1986-1996 (2009).
179. Jain, R. et al. Cardiac neural crest orchestrates remodeling and functional maturation of mouse semilunar valves. J. Clin. Invest. 121, 422-430 (2011).
180. Rutenberg, J. B. et al. Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors. Development 133, 4381-4390 (2006). (Pubitemid 44830679)
181. Watanabe, Y. et al. Activation of Notch1 signaling in cardiogenic mesoderm induces abnormal heart morphogenesis in mouse. Development 133, 1625-1634 (2006). (Pubitemid 43810970)
182. Luna-Zurita, L. et al. Integration of a Notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine cardiac valve formation. J. Clin. Invest. 120, 3493-3507 (2010).
183. Rentschler, S. et al. Notch signaling regulates murine atrioventricular conduction and the formation of accessory pathways. J. Clin. Invest. 121, 525-533 (2011).
184. Garg, V. et al. Mutations in NOTCH1 cause aortic valve disease. Nature 437, 270-274 (2005). (Pubitemid 41294491)
185. Mohamed, S. A. et al. Novel missense mutations (p. T596M and p. P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem. Biophys. Res. Commun. 345, 1460-1465 (2006). (Pubitemid 43817895)
186. McKellar, S. H. et al. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J. Thorac. Cardiovasc. Surg. 134, 290-296 (2007). (Pubitemid 47088578)
187. Nigam, V. & Srivastava, D. Notch1 represses osteogenic pathways in aortic valve cells. J. Mol. Cell. Cardiol. 47, 828-834 (2009).
188. Nus, M. et al. Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL. Arterioscler. Thromb. Vasc. Biol. 31, 1580-1588 (2011).
189. Isidor, B. et al. Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nature Genet. 43, 306-308 (2011).
190. Simpson, M. A. et al. Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nature Genet. 43, 303-305 (2011).
191. Lowell, S., Jones, P., Le Roux, I., Dunne, J. & Watt, F. M. Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters. Curr. Biol. 10, 491-500 (2000). (Pubitemid 30308306)
192. Thelu, J., Rossio, P., Favier, B. & Thilu, J. Notch signalling is linked to epidermal cell differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC Dermatol. 2, 7 (2002).
193. Rangarajan, A. et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 20, 3427-3436 (2001). (Pubitemid 32634350)
194. Mammucari, C. et al. Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. Dev. Cell 8, 665-676 (2005). (Pubitemid 40585290)
195. Blanpain, C., Lowry, W. E., Pasolli, H. A. & Fuchs, E. Canonical notch signaling functions as a commitment switch in the epidermal lineage. Genes Dev. 20, 3022-3035 (2006). (Pubitemid 44771736)
196. Nicolas, M. et al. Notch1 functions as a tumor suppressor in mouse skin. Nature Genet. 33, 416-421 (2003). (Pubitemid 36278861)
197. Demehri, S. et al. Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol. 6, e123 (2008).
198. Di Piazza, M., Nowell, C. S., Koch, U., Durham, A.-D. & Radtke, F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell 22, 479-493 (2012).
199. Demehri, S. et al. Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell 22, 494-505 (2012).
200. Pickering, C. R. et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 3, 770-781 (2013).
201. Jithesh, P. V. et al. The epigenetic landscape of oral squamous cell carcinoma. Br. J. Cancer 108, 370-379 (2013).
202. Yoshida, R. et al. The pathological significance of Notch1 in oral squamous cell carcinoma. Lab. Invest. 93, 1068-1081 (2013).
203. Pourquii, O. Vertebrate segmentation: from cyclic gene networks to scoliosis. Cell 145, 650-663 (2011).
204. Dequiant, M.-L. et al. A complex oscillating network of signaling genes underlies the mouse segmentation clock. Science 314, 1595-1598 (2006).
205. Dias, A. S., de Almeida, I., Belmonte, J. M., Glazier, J. A. & Stern, C. D. Somites without a clock. Science 343, 791-795 (2014).
206. Bulman, M. P. et al. Mutations in the human Delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis. Nature Genet. 24, 438-441 (2000). (Pubitemid 30187449)
207. Cornier, A. S. et al. Mutations in the MESP2 gene cause spondylothoracic dysostosis/Jarcho-Levin syndrome. Am. J. Hum. Genet. 82, 1334-1341 (2008).
208. Sparrow, D. B. et al. A mechanism for gene-environment interaction in the etiology of congenital scoliosis. Cell 149, 295-306 (2012).
209. Lewis, J. Rules for the production of sensory cells. Ciba Found. Symp. 160, 25-39; discussion 40-53 (1991).
210. Kiernan, A. E., Cordes, R., Kopan, R., Gossler, A. & Gridley, T. The Notch ligands DLL1 and JAG2 act synergistically to regulate hair cell development in the mammalian inner ear. Development 132, 4353-4362 (2005). (Pubitemid 41576696)
211. Haddon, C., Jiang, Y. J., Smithers, L. & Lewis, J. Delta-Notch signalling and the patterning of sensory cell differentiation in the zebrafish ear: evidence from the mind bomb mutant. Development 125, 4637-4644 (1998). (Pubitemid 29027194)
212. Haddon, C. et al. Hair cells without supporting cells: further studies in the ear of the zebrafish mind bomb mutant. J. Neurocytol. 28, 837-850 (1999). (Pubitemid 30617133)
213. Tateya, T., Imayoshi, I., Tateya, I., Ito, J. & Kageyama, R. Cooperative functions of Hes/Hey genes in auditory hair cell and supporting cell development. Dev. Biol. 352, 329-340 (2011).
214. Kiernan, A. E. et al. The Notch ligand Jagged1 is required for inner ear sensory development. Proc. Natl Acad. Sci. USA 98, 3873-3878 (2001). (Pubitemid 32249864)
215. Tsai, H. et al. The mouse slalom mutant demonstrates a role for Jagged1 in neuroepithelial patterning in the organ of Corti. Hum. Mol. Genet. 10, 507-512 (2001). (Pubitemid 32181673)
216. Vrijens, K. et al. Ozzy, a Jag1 vestibular mouse mutant, displays characteristics of Alagille syndrome. Neurobiol. Dis. 24, 28-40 (2006). (Pubitemid 44416210)
217. McCright, B., Lozier, J. & Gridley, T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development 129, 1075-1082 (2002). (Pubitemid 34874130)
218. Yanger, K. et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev. 27, 719-724 (2013).
219. Pajvani, U. B. et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nature Med. 19, 1054-1060 (2013).
220. Zender, S. et al. A critical role for Notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 23, 784-795 (2013).
221. Villanueva, A. et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 143, 1660-1669.e7 (2012).
222. Raouf, A. et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 3, 109-118 (2008).
223. Bouras, T. et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3, 429-441 (2008).
224. Pece, S. et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell Biol. 167, 215-221 (2004). (Pubitemid 39435065)
225. Stylianou, S., Clarke, R. B. & Brennan, K. Aberrant activation of Notch signaling in human breast cancer. Cancer Res. 66, 1517-1525 (2006). (Pubitemid 43259933)
226. Robinson, D. R. et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Med. 17, 1646-1651 (2011).
227. Qiu, M. et al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett. 328, 261-270 (2013).
228. Gallahan, D. et al. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res. 56, 1775-1785 (1996). (Pubitemid 26118213)
229. Robbins, J., Blondel, B. J., Gallahan, D. & Callahan, R. Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. J. Virol. 66, 2594-2599 (1992).
230. Landor, S. K.-J. et al. Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms. Proc. Natl Acad. Sci. USA 108, 18814-18819 (2011).
231. Šale, S., Lafkas, D. & Artavanis-Tsakonas, S. Notch2 genetic fate mapping reveals two previously unrecognized mammary epithelial lineages. Nature Cell Biol. 15, 451-460 (2013).
232. Parr, C., Watkins, G. & Jiang, W. G. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int. J. Mol. Med. 14, 779-786 (2004).
233. O'Neill, C. F. et al. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am. J. Pathol. 171, 1023-1036 (2007). (Pubitemid 47440999)
234. Stephens, P. J. et al. Whole exome sequencing of adenoid cystic carcinoma. J. Clin. Invest. 123, 2965-2968 (2013).
235. Deangelo, D. J. et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J. Clin. Oncol. Abstr. 24, 6585 (2006).
236. Ridgway, J. et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083-1087 (2006). (Pubitemid 46018529)
237. Li, J.-L. et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 67, 11244-11253 (2007). (Pubitemid 350248550)
238. Kuramoto, T. et al. Dll4-Fc, an inhibitor of Dll4-Notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-KB activity. Mol. Cancer Ther. 11, 2578-2587 (2012).
239. Jenkins, D. W. et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol. Cancer Ther. 11, 1650-1660 (2012).
240. Scehnet, J. S. et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109, 4753-4760 (2007). (Pubitemid 46827768)
241. Noguera-Troise, I. et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032-1037 (2006). (Pubitemid 46018516)
242. Zhao, X.-C. et al. Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells. Neoplasia 15, 815-825 (2013).
243. Li, K. et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J. Biol. Chem. 283, 8046-8054 (2008).
244. Tolcher, Anthony, W. et al. A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors. J. Clin. Oncol. Abstr. 30, 3025 (2012).
245. Davis, S. L. et al. Abstract B48: a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors. Mol. Cancer Ther. 12, B48 (2013).
246. Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341-350 (2013).
247. Tolcher, A. W. et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 30, 2348-2353 (2012).
248. Rosen, L. B. et al. The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimers Dement. 2, S79 (2006).
249. Krop, I. et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 30, 2307-2313 (2012).
250. Kolb, E. A. et al. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma;-secretase inhibitor targeting notch signaling. Pediatr. Blood Cancer 58, 815-818 (2012).
251. Luistro, L. et al. Preclinical profile of a potent gamma;-secretase inhibitor targeting Notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 69, 7672-7680 (2009).
252. Strosberg, J. R. et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur. J. Cancer 48, 997-1003 (2012).
253. Wang, Z. et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim. Biophys. Acta 1806, 258-267 (2010).
254. Yu, S.-D., Liu, F.-Y. & Wang, Q.-R. Notch inhibitor: a promising carcinoma radiosensitizer. Asian Pac. J. Cancer Prev. 13, 5345-5351 (2012).
255. Timme, C. R., Gruidl, M. & Yeatman, T. J. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells. Apoptosis 18, 1163-1174 (2013).
256. Meng, R. D. et al. gamma;-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 69, 573-582 (2009).
257. Liu, S., Breit, S., Danckwardt, S., Muckenthaler, M. U. & Kulozik, A. E. Downregulation of Notch signaling by gamma;-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Ann. Hematol. 88, 613-621 (2009).
258. Sahebjam, S. et al. A phase I study of the combination of RO4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br. J. Cancer 109, 943-949 (2013).
259. Diaz-Padilla, I. et al. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest. New Drugs 31, 1182-1191 (2013).
260. Richter, S. et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest. New Drugs 32, 243-249 (2014).
261. Mizutari, K. et al. Notch inhibition induces cochlear hair cell regeneration and recovery of hearing after acoustic trauma. Neuron 77, 58-69 (2013).
262. Slowik, A. D. & Bermingham-McDonogh, O. Hair cell generation by Notch inhibition in the adult mammalian cristae. J. Assoc. Res. Otolaryngol. 14, 813-828 (2013).
263. Jin, S. et al. Notch signaling regulates platelet-derived growth factor receptor-β expression in vascular smooth muscle cells. Circ. Res. 102, 1483-1491 (2008).
264. Eickelberg, O. & Morty, R. E. Transforming growth factor β/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited. Trends Cardiovasc. Med. 17, 263-269 (2007). (Pubitemid 350087696)
265. O'Callaghan, D. S. et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nature Rev. Cardiol. 8, 526-538 (2011).
266. Tran, I. T. et al. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J. Clin. Invest. 123, 1590-1604 (2013).
267. Chen, Y. et al. Inhibition of Notch signaling by a gamma;-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS ONE 7, e46512 (2012).
268. Siemers, E. R. et al. Effects of a gamma;-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602-604 (2006). (Pubitemid 43739900)
269. Fleisher, A. S. et al. Phase 2 safety trial targeting amyloid β production with a gamma;-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031-1038 (2008).
270. Pandya, K. et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br. J. Cancer 105, 796-806 (2011).
271. Farnie, G., Willan, P. M., Clarke, R. B. & Bundred, N. J. Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. PLoS ONE 8, e56840 (2013).
272. Ma, Y. et al. Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem. Biophys. Res. Commun. 431, 274-279 (2013).
273. Jin, R. et al. Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells. Neurosci. Lett. 534, 316-321 (2013).
274. Shepherd, C. et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 27, 650-660 (2013).
275. Yao, J. et al. Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/β-catenin. Cancer Biol. Ther. 14, 833-839 (2013).
276. Slowing, I. I., Trewyn, B. G., Giri, S. & Lin, V. S. Y. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv. Funct. Mater. 17, 1225-1236 (2007). (Pubitemid 46847636)
277. Mamaeva, V. et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol. Ther. J. Am. Soc. Gene Ther. 19, 1538-1546 (2011).
278. Beckstead, B. L. et al. Methods to promote Notch signaling at the biomaterial interface and evaluation in a rafted organ culture model. J. Biomed. Mater. Res. Part A 91, 436-446 (2009).
279. Kovall, R. A. & Blacklow, S. C. Mechanistic insights into Notch receptor signaling from structural and biochemical studies. Curr. Top. Dev. Biol. 92, 31-71 (2010).
280. Hock, B. et al. PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor. Proc. Natl Acad. Sci. USA 95, 9779-9784 (1998). (Pubitemid 28415246)
281. LaVoie, M. J. & Selkoe, D. J. The Notch ligands, Jagged and Delta, are sequentially processed by aα-secretase and presenilin/gamma;-secretase and release signaling fragments. J. Biol. Chem. 278, 34427-34437 (2003). (Pubitemid 37553289)
282. Higaki, J., Quon, D., Zhong, Z. & Cordell, B. Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 14, 651-659 (1995).
283. Barthet, G., Georgakopoulos, A. & Robakis, N. K. Cellular mechanisms of gamma;-secretase substrate selection, processing and toxicity. Prog. Neurobiol. 98, 166-175 (2012).
284. Wolfe, M. S. gamma;-secretase as a target for Alzheimer's disease. Adv. Pharmacol. 64, 127-153 (2012).
285. Louvi, A. & Artavanis-Tsakonas, S. Notch and disease: a growing field. Semin. Cell Dev. Biol. 23, 473-480 (2012).
286. Willander, K. et al. NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients. BMC Cancer 13, 274 (2013).
287. Zong, Y. & Stanger, B. Z. Molecular mechanisms of bile duct development. Int. J. Biochem. Cell Biol. 43, 257-264 (2011).
288. Massi, D. & Panelos, J. Notch signaling and the developing skin epidermis. Adv. Exp. Med. Biol. 727, 131-141 (2012).
289. Martignetti, J. A. et al. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. Am. J. Hum. Genet. 92, 1001-1007 (2013).
290. Lee, J. Mutations in PDGFRB and NOTCH3 are the first genetic causes identified for autosomal dominant infantile myofibromatosis. Clin. Genet. 84, 340-341 (2013).
291. Michailidis, C. et al. Notch2, Notch4 gene polymorphisms in psoriasis vulgaris. Eur. J. Dermatol. 23, 146-153 (2013).
292. Sun, W. et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 74, 1091-1104 (2013).
293. Wang, N. J. et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl Acad. Sci. USA 108, 17761-17766 (2011).
294. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
295. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
296. Dunwoodie, S. L. The role of Notch in patterning the human vertebral column. Curr. Opin. Genet. Dev. 19, 329-337 (2009).
297. Regan, J. & Long, F. Notch signaling and bone remodeling. Curr. Osteoporos. Rep. 11, 126-129 (2013).
298. Fouillade, C., Monet-LeprKtre, M., Baron-Menguy, C. & Joutel, A. Notch signalling in smooth muscle cells during development and disease. Cardiovasc. Res. 95, 138-146 (2012).
299. Benedito, R. & Hellstrqm, M. Notch as a hub for signaling in angiogenesis. Exp. Cell Res. 319, 1281-1288 (2013).